Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$8 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-4.7 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
2.5
Industry P/E
--
EV/EBITDA
-2.8
Div. Yield
0 %
Debt to Equity
0.5
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
5,412,853
CFO
$-40.81 Mln
EBITDA
$-60.54 Mln
Net Profit
$-66.88 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mainz Biomed BV (MYNZ)
| -58.2 | -38.3 | -58.2 | -84.0 | -87.7 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
|---|---|---|---|
|
Mainz Biomed BV (MYNZ)
| -74.1 | -83.7 | -31.7 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops... PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany. Address: Robert Koch Strasse 50, Mainz, Germany, 55129 Read more
CEO & Executive Director
Mr. Guido Baechler
CEO & Executive Director
Mr. Guido Baechler
Headquarters
Mainz
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Mainz Biomed BV (MYNZ) is $0.47 (NASDAQ) as of 02-Apr-2026 09:30 EDT. Mainz Biomed BV (MYNZ) has given a return of -87.69% in the last 3 years.
Since, TTM earnings of Mainz Biomed BV (MYNZ) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Mainz Biomed BV (MYNZ) are Rs 4.43 and Rs 0.45 as of 05-Apr-2026.
Mainz Biomed BV (MYNZ) has a market capitalisation of $ 8 Mln as on 30-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Mainz Biomed BV (MYNZ), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.38
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.